Neuronetics Reports Third Quarter 2026 Financial and Operating Results
Neuronetics, Inc. (STIM) filed an SEC Form 8-K — Results of Operations and Financial Condition. Exhibit 99.1 Neuronetics Reports Third Quarter 2026 Financial and Operating Results MALVERN, PA., November 4, 2026 – Neuronetics, Inc. (NASDAQ: STIM) (the “Company” or “Neuronetics”), a leader in interventional mental health and provider of NeuroStar ® TMS technology and direct p
How this was made
The 30-second read
Why it matters
The earnings release provides fresh financial data and reaffirmed FY guidance, offering traders a basis for short‑term positioning.
Market read
First‑report earnings with better-than‑expected metrics could attract short‑term buying interest.
What to watch
The pending 510(k) for accelerated TMS and PTSD partnership could drive longer‑term upside not reflected in the short‑term price.
Background
Neuronetics is a Nasdaq‑listed provider of TMS therapy devices and operates the Greenbrook clinic network.
Ticker impact
Neuronetics filed its Q3 2026 earnings on Form 8‑K, reporting revenue up 12.5% YoY and a narrowed net loss.
potential modest upside as investors price in stronger revenue and tighter losses
The company posted higher revenue, better gross margin and a loss of $1.7 M versus $9.0 M a year ago, plus reaffirmed FY guidance, which may lift the stock.
Market effects
Improved results may boost sentiment in the mental‑health device sector.
Limited to U.S. and Canadian investors focused on neuro‑technology.
Minimal global impact beyond niche medical‑device markets.
Counterpoint
If the market had already priced in the revenue growth, the modest loss improvement may not move the stock significantly.
Key entities
- companyNeuronetics, Inc.
NASDAQ: STIM, provider of NeuroStar TMS technology.
